Immunocore Holdings Gross Profit Over Time
| IMCR Stock | USD 32.12 0.30 0.93% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immunocore Holdings Performance and Immunocore Holdings Correlation. Immunocore |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunocore Holdings. If investors know Immunocore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunocore Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 8.22 | Earnings Share (0.95) | Revenue Per Share 5.942 | Quarterly Revenue Growth 0.237 | Return On Assets (0.05) |
The market value of Immunocore Holdings is measured differently than its book value, which is the value of Immunocore that is recorded on the company's balance sheet. Investors also form their own opinion of Immunocore Holdings' value that differs from its market value or its book value, called intrinsic value, which is Immunocore Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunocore Holdings' market value can be influenced by many factors that don't directly affect Immunocore Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunocore Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunocore Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunocore Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Immunocore Holdings and related stocks such as Arcellx, Ventyx Biosciences, and Vaxcyte Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACLX | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (326 K) | (629 K) | (1 M) | (2.2 M) | 108.3 M | 113.7 M |
| VTYX | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (30 K) | (470 K) | (941 K) | (894 K) |
| PCVX | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.4 M) | (1.8 M) | (9.2 M) | (75 M) | (71.2 M) |
| VRDN | 1.4 M | 1.4 M | 1.4 M | 1.8 M | 1.1 M | 66 K | 789 K | 4 M | 8.4 M | (28.3 M) | (27.3 M) | 2.3 M | 1 M | (1 M) | (1.1 M) |
| GLUE | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (72 K) | (537 K) | (2.1 M) | (8.6 M) | (6.2 M) | (5.9 M) |
| DSGN | (820) | (820) | (820) | (820) | (820) | (820) | (820) | (820) | (820) | (820) | (4.8 K) | (129 K) | (466 K) | (537 K) | (510.1 K) |
| ERAS | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (310 K) | (540 K) | (829 K) | (2.6 M) | (3.7 M) | (3.5 M) |
| MIRM | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (324 K) | (623 K) | 17.2 M | 64.7 M | 139.3 M | 146.3 M |
| LRMR | (70 K) | (70 K) | (70 K) | (70 K) | (70 K) | (70 K) | (212 K) | (188 K) | (261 K) | (78 K) | (155 K) | (326 K) | (272 K) | (311 K) | (326.6 K) |
| KALV | 1.5 M | 1.5 M | 1.5 M | 415 K | 1.8 M | 29 K | 1.5 M | 8.4 M | 16.1 M | 12.6 M | 12 M | (743 K) | (802 K) | (86.2 M) | 29 K |
| LYRA | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | (27 K) | (95 K) | 285 K | 296 K | (46.5 M) | (44.1 M) |
Immunocore Holdings and related stocks such as Arcellx, Ventyx Biosciences, and Vaxcyte Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Immunocore Holdings minus its cost of goods sold. It is profit before Immunocore Holdings operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Immunocore Holdings | IMCR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | United Kingdom |
| Exchange | NASDAQ Exchange |
USD 32.12
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.